Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats (Q44244722)

1 December 2017

title

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats (English)

1 reference

1 December 2017

1 reference

Christian L Brand

1

1 reference

1 December 2017

Jeppe Sturis

2

1 reference

1 December 2017

Carsten F Gotfredsen

3

1 reference

1 December 2017

Jan Fleckner

4

1 reference

1 December 2017

Christian Fledelius

5

1 reference

1 December 2017

Bo F Hansen

6

1 reference

1 December 2017

Birgitte Andersen

7

1 reference

1 December 2017

Ji-Ming Ye

8

1 reference

1 December 2017

Per Sauerberg

9

1 reference

1 December 2017

Karsten Wassermann

10

1 reference

1 December 2017

language of work or name

1 reference

10 December 2002

1 reference

American Journal of Physiology - Endocrinology and Metabolism

1 December 2017

published in

1 reference

1 December 2017

volume

284

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

E841-54

1 reference

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Long-term high-fat feeding leads to severe insulin resistance but not diabetes in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Role of liver in pathophysiology of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Is insulin resistance the principal cause of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

No limiting role for glycogenin in determining maximal attainable glycogen levels in rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Mild streptozotocin diabetes in the Göttingen minipig. A novel model of moderate insulin deficiency and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

A review of rosiglitazone in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00348.2002

10.1152/AJPENDO.00348.2002

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference